IUGNF (Imugene) Shiller PE Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Imugene Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Imugene  (OTCPK:IUGNF) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Imugene Shiller PE Ratio Related Terms


Imugene Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Imugene's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imugene Shiller PE Ratio Chart

Imugene Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Imugene Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

IUGNF vs VRTX, REGN, MRNA: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Imugene's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Imugene Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Imugene's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Imugene's Shiller PE Ratio falls into.



Imugene Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Imugene's E10 for the fiscal year that ended in Jun26 is calculated as:

For example, Imugene's adjusted earnings per share data for the fiscal year that ended in Jun26 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun26 (Change)*Current CPI (Jun26)
=-0.2189/136.4868*136.4868
=-0.219

Current CPI (Jun26) = 136.4868.

Imugene Annual Data

Earnings per Share (Diluted) CPI Adj_EPS
201706 -0.031 0.000
201806 -0.040 0.000
201906 -0.053 0.000
202006 -0.059 0.000
202106 -0.100 0.000
202206 -0.166 0.000
202306 -0.138 0.000
202406 -0.471 0.000
202506 -0.140 131.551 -0.145
202606 -0.219 136.487 -0.219

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Imugene Business Description

Other Exchanges ILA:GermanyIMU:Australia
Address 4-6 Bligh Street, Suite 12.01, Level 12, Sydney, NSW, AUS, 2000
Imugene Ltd is an Australian clinical-stage immuno-oncology company developing therapies that activate the immune system to identify and destroy cancer cells. Its pipeline includes oncolytic virus candidates such as CF33/CD (vaxinia) and CHECKvacc, and B-cell immunotherapy assets including the CD19-targeting allogeneic CAR T therapy azer-cel (azercabtagene zapreleucel), developed for blood cancers. The company operates as a single reportable segment focused on research and development of novel cancer treatments, conducting clinical trials across Australia and the United States. As a clinical-stage business, Imugene generates no product revenue; it funds operations through equity raises, licensing arrangements and partnership deals, including collaborations with larger pharmaceutical and biotechnology companies. Its customers and collaborators are primarily oncology researchers, hospitals and clinical trial sites rather than commercial end users.